
Opinion|Videos|April 12, 2024
Steroid-Refractory cGvHD: Emerging Treatment Options
This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
Episodes in this series


















